Sunshine plans an aggressive clinic opening schedule in rural and suburban areas along with franchising. Sunshine Care Virtual Clinics and SunshineCare.Online are companies created from the result of prior ObamaCare In…

The post Sunshine Care to Open Newest Clinic Nov. 1, 2022, Using Mostly ReStore Store/Habitat for Humanity Materials first appeared on Enrose Magazine.

Drag Racing Community Mourns the Loss of a Life Well Raced

Tom Hoover’s 1966 Fishbowl Dragster
Hoover with friend Steve Anderson (far right) showcasing his 1966 front-end \”fishbowl\” dragster that Hot Rod magazine called most beautiful dragster ever built in the March 2015 issue.

MINNEAPOLIS – October 24, 2022 – (Newswire.com)

Showtime Racing announces the renowned National Hot Rod Association (NHRA) professional drag racer, beloved husband, and father of four, Tom “Showtime” Hoover passed away Friday evening at the age of 81 from natural causes compounded by health complications. Ironically, for a man who raced the loudest automobiles in motorsports, Hoover died peacefully at St. Joseph’s hospital just minutes from his MN home and his hometown racetrack Brainerd International Raceway. 

Hoover was a cornerstone of the NHRA, IHRA and AHRA professional drag racing community for almost four decades, having built a 35-year career of competitive racing achievements while delivering extreme thrills for fans in both of drag racing’s major racing categories: Top Fuel Dragster and predominantly in Funny Car. He raced from the 1960s to the early 2000s, creating a worldwide reputation for showmanship and performance on the track. This reputation earned him the nickname “Showtime”, a nod not only to his track record, but also for the stunning paint jobs on his cars by his painter and lifelong friend, Reed Holmes, as well as his colorful on-camera interviews and his candor with fans.

Hoover is survived by his wife of nearly 50 years Betten Hoover, and his children Trent Hoover (deceased in 2018), Troy Hoover, Leighe “Paige” Steers, and Landon Hoover, as well as 10 grandchildren and three great-grandchildren

“Anyone who ever met Tom, would certainly remember that very moment,” said his wife Betten Hoover (on left) who penned the book Out of the Groove about living life on the road. “His presence and personality were both larger than life and he could put a smile on anyone’s face with his wit and humor. He was fearless in his racing pursuits and lived for the sport, but it was his family legacy that meant the most to Tom.” 

While Hoover was determinately humble, his notable list of racing accomplishments throughout his career in funny car included the following:

Hoover was one of the first five funny car drivers in drag racing to break the 6-second quarter mile, 5-second quarter mile and 4-second quarter mile and is the only driver to be among the first to break all three milestones over three decades while racing in funny car.

In 1965, Hoover’s first “major” victory came at the American Hot Rod Association (AHRA) Winter Nationals in Phoenix Arizona. At just 24 years old, he was the youngest driver to ever win such a major event.

In the early 1970s, Hoover became one of the first dragster drivers to take on the challenge of driving and owning the then-newest class of drag racing vehicles, the nearly uncontrollable “Funny Car”. Hoover went on to win the AHRA Funny Car Championship three years in a row in 1976-77-78.

In 1977 Hoover won the NHRA Grand Nationals in Montreal, Canada. He followed up that victory in 1979, winning the NHRA Winter Nationals in Pomona, Ca. and went on to rank among the top ten NHRA Funny Car drivers in the nation almost every year through the late 1990s.

In the 1980s, Hoover became the fifth of eight members to the prestigious Cragar Five Second Club with a recorded elapsed time of 5.95 seconds in the quarter mile. The ’80s also saw Hoover bring international prominence to drag racing by racing at Santa Pod Raceway in Podington, England, where he partnered with UK-born funny car driver Bill “Cannonball” Sherratt, who became his closest collaborator and best friend. Tom went on to become an international ambassador of drag racing, bringing his passion for speed and pushing the limits of performance to Canada, Mexico and even earning the title of “World Champion of Australia” in a dragster in 1995.

Throughout the 1990s, Hoover continued to rack up wins, winning the National Race at Phoenix in 1992, the Fram Autolite Nationals in Sonoma, CA, in 1993, and the Pontiac Excitement Nationals in Columbus, Ohio in 1997, which he won just nine weeks after undergoing quadruple by-pass heart surgery, against the better judgment of his doctors.

In 2014, Hoover was awarded drag racing’s highest honor, induction into the International Drag Racing Hall of Fame. That was an incredible honor to him given his parents George – who was Tom’s crew chief well into his 80s – and Ruth Hoover were also inducted decades before him. 

Most recently, in 2016, the NHRA presented him with a special “Legend of the Sport” Award.

In recent years, Hoover was quoted as saying, “The greatest thing that I gained by being a professional in this sport was the many friendships that I made both here and abroad and the many memories that now sustain me. Memories anchor our lives on what was and what is still to be as we race into the future.”

Hoover had been in declining health in recent years but would still be seen at a few NHRA races each year most notably the NHRA Brainerd Nationals in his native Minnesota, catching up with old friends and fans alike. In his last years, Hoover could be spotted at Cacklefests with friend Steve Anderson showcasing his 1966 front-end “fishbowl” dragster that Hot Rod magazine called the most beautiful dragster ever built in the March 2015 issue. That car was exhibited as an art sculpture at the Weisman Art Museum in 2017. Tom Hoover’s racing family archive is housed in permanent collection of the Minnesota History Center in St. Paul, Minnesota.

To honor and celebrate Hoover’s life, the Hoovers are planning a Cacklefest and celebration of his life in Minneapolis, MN, to be announced shortly.

Media Contact: Paige Hoover-Steers, Cell: 312-402-2289, phooverpr@yahoo.com

#          #          #

Contact Information:

Paige Hoover-Steers

VP, Showtime Racing

phooverpr@yahoo.com

312 402 2289

Press Release Service
by
Newswire.com

Original Source:

Showtime Racing Announces the Death of Legendary Driver Tom ‘Showtime’ Hoover

Ritual combines 1:1 guidance from experienced relationship experts with scientifically validated tools in a user-friendly platform

Logo HeyRitual…

The post With $2M in Pre-Seed Funding, HeyRitual Launches to Take Couples Therapy Into the Digital Age first appeared on Enrose Magazine.

Thierry also explains how he used to take players on 1-v-1 and who he looked up to during

Power chair experts team up to assist mobility-impaired consumers with a broader range of medical conditions

WHILL model F and C2 with Stealth Acce…

The post WHILL Power Chairs Announces Partnership With Stealth Products first appeared on Enrose Magazine.

Virtual workshop on Nov. 17-18 bridges the gap between critical stakeholders to pinpoint today’s challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.

Be the Match
Be the Match

MINNEAPOLIS – October 24, 2022 – (Newswire.com)

The AcCELLerate Forum, a joint partnership between the American Society for Transplantation and Cellular Therapy (ASTCT™), the Center for International Blood and Marrow Transplant Research® (CIBMTR®), and the National Marrow Donor Program® (NMDP)/Be The Match®, brings key stakeholders together to identify ongoing needs and opportunities in cell and gene therapy for advocacy, measurement of value and impact and sustainability. The virtual workshop on Nov. 17-18, 2022, joins providers, payers, government agencies and industry members who will work together to define essential factors needed to create a sustainable cell and gene therapy ecosystem. 

“NMDP/Be The Match is proud to be one of the sponsors of this important forum that has interests for all key stakeholders across the ecosystem,” said Jeffery Auletta, M.D., Senior Vice President, Patient Outcomes and Experience, of NMDP/Be The Match, Chief Scientific Director, CIBMTR. “Our established relationships with a global network of transplant centers and cell and gene therapy developers uniquely position NMDP/Be The Match to bring these experts together to identify the needs and opportunities in this field for advocacy, measurement, and sustainability.”

Dr. Auletta will join industry and transplant center partners and other professionals to address the question, “Are Center-Specific Outcomes Possible for CAR T-cell Immunotherapy?” The participants will focus on the perspectives of the payer, data acquisition and analysis, and center perspectives in defining outcomes for CAR T cells. They will also discuss healthcare inequity, specifically barriers to access and their impact on cell therapy outcomes. The speakers will incorporate the evolving cell therapy landscape from industry collaboration to clinical trials and real-world treatment in their presentations and in a moderator-led roundtable with attendee participation. Visit the event website to register and see the complete schedule and list of presenters.

In addition to NMDP/Be The Match, the event co-hosts include:

The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. For more information about ASTCT, visit www.astct.org and follow us on Twitter, @ASTCT.

The CIBMTR, a research collaboration between the NMDP/Be The Match and the Medical College of Wisconsin, facilitates critical cellular therapy research through a clinical database of more than 600,000 patients from more than 350 centers worldwide, with a biospecimen repository of more than 195,000 samples. 

Background:

The National Marrow Donor Program® (NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With 35 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR®—a collaboration with the Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care.

Contact Information:

Phyllis Grabot

phyllis@clarityqst.com

Bonnie Quintanilla

bonnie@clarityqst.com

Press Release Service
by
Newswire.com

Original Source:

The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy

The post The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy first appeared on Enrose Magazine.

Test offers EoE patients a simple, clinically proven method to control their disease. “…Beyond thrilled to use this at Phoenix Children’s Hospital…” – Dr. Schroeder, Medical Director, Eosinophilic Disease Clinic, Phoenix Children’s Hospital

AURORA, Colo. – October 24, 2022 – (Newswire.com)

Clinicians with the Gastrointestinal Eosinophilic Disease Program at the Digestive Health Institute, Children’s Hospital of Colorado, performed the Esophageal String Test^® (EST) on a patient in early September. The test will be offered regularly at the hospital.

The EST was also performed on patients in the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital. 

“I am now beyond thrilled to use this new esophageal surveillance technique at Phoenix Children’s and for my patients with eosinophilic gastrointestinal disorders. The EST is a game-changer for my patients who are looking for a less invasive and less expensive way to screen their disease activity,” said Dr. Shauna Schroeder, Medical Director for the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital. She further stated “Having trained in Denver, I had experience using the EST as a research tool in patients with eosinophilic esophagitis. I am now able to more granularly adjust medications and diets improving the care of my patients with eosinophilic esophagitis.”

The Esophageal String Test^® utilizes a simple collection device, the EnteroTracker^®, to collect upper gastrointestinal samples from adults and children.  The samples are sent to an independent reference lab for analysis of disease activity. Several other clinics around the country are planning to offer the test soon.

About EnteroTrack 

EnteroTrack, an early-stage company, develops simple-to-use, minimally invasive technologies to sample gastrointestinal (GI) mucosal content that can be assayed for various biomarkers of disease. The company’s platform technology, the EnteroTracker^® is initially being used to support clinical monitoring of Eosinophilic Esophagitis in adults and children without need for sedation, advanced training, or complex procedures. Clinical studies evaluating the utility of the EnteroTracker^® for additional applications including Esophageal Adenocarcinoma, Barrett’s Esophagus, GERD, GI microbiome, food allergy testing, and others are currently underway.

Contact Information:

Robin Shandas

CEO, Media and Investor Inquiries

robin.shandas@enterotrack.com

Brookelynn Stillwell

General Inquiries

brookelynn.stillwell@enterotrack.com

Press Release Service
by
Newswire.com

Original Source:

Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US

The post Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US first appeared on Enrose Magazine.

Gb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

GB Sciences

LAS VEGAS – October 24, 2022 – (Newswire.com)

Gb Sciences, Inc. (“GbS”; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS’ proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS’ proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company’s first non-cannabis formulations to advance in preclinical studies.

“We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations,” said Dr. Andrea Small-Howard, Gb Sciences’ President and Chief Science Officer. “This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs.”

For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.

The PhAROS^TM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com. 

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Media Contact

Alexis Quintal

grow@rosarium.work

Contact Information:

Madeleine Moench

madeleine@newswire.com

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

The post Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study first appeared on Enrose Magazine.

First joint research project between Sanofi and the BioMed X Institute, co-creation of a next-generation virtual patient engine for clinical translation of drug candidates

…

The post BioMed X Inks Research Collaboration With Sanofi on Artificial Intelligence for Drug Development first appeared on Enrose Magazine.

Pop star Madison Beer gets real about her skin struggles over the years, and shares her perfected everyday beauty routine. Shop this beauty routine: PanOxyl Acne Foaming Wash: Laneige Cream Skin Toner & Moisturizer: Herbivore Rose Quartz Facial Roller: Drunk Elephant Lala Retro Whipped Moisturizer with Ceramides: Caudalie Beauty Elixir: La Mer The Eye Concentrate: […]